* ARIAD announces FDA full approval and label update for
Iclusig (ponatinib) based on long-term efficacy and safety data
from Phase 2 PACE clinical trial
The post BRIEF-ARIAD announces FDA full approval and label update for Iclusig (ponatinib) appeared first on NASDAQ.